Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines  Dawn B. Beaulieu, Ashwin N. Ananthakrishnan, Christopher Martin, Russell D. Cohen, Sunanda V. Kane, Uma Mahadevan  Clinical Gastroenterology and Hepatology  Volume 16, Issue 1, Pages 99-105 (January 2018) DOI: 10.1016/j.cgh.2017.08.041 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Proportion of infants with protective titers to HiB and tetanus vaccine, by maternal biologic use. A total of 46 (38 biologic exposed, 8 unexposed) and 49 (41 biologic exposed, 8 unexposed) infants had an available vaccine titer response to HiB and tetanus, respectively. Clinical Gastroenterology and Hepatology 2018 16, 99-105DOI: (10.1016/j.cgh.2017.08.041) Copyright © 2018 AGA Institute Terms and Conditions

Figure 2 Association between the cord blood concentration of infliximab and the response to HiB or tetanus toxoid vaccines. (A) HiB. The median infliximab cord blood levels in infants with adequate and inadequate serologic response to HiB were 24.3 and 43.0 mcg/mL, respectively (P = .30). (B) Tetanus toxoid. The median infliximab cord blood levels in infants with adequate and inadequate serologic response to tetanus were 31.4 and 41.5 mcg/mL, respectively (P = .93). Clinical Gastroenterology and Hepatology 2018 16, 99-105DOI: (10.1016/j.cgh.2017.08.041) Copyright © 2018 AGA Institute Terms and Conditions